机译:口服脊髓灰质炎病毒疫苗的演变和与模拟循环疫苗衍生脊髓灰质炎病毒(cVDPVs)的风险有关的见解
Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL, USA;
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Atlanta, GA, USA;
Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL, USA;
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Atlanta, GA, USA;
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Atlanta, GA, USA;
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Atlanta, GA, USA;
World Health Organization, Global Polio Eradication Initiative, Geneva, Switzerland;
Centers for Disease Control and Prevention, Center for Global Health, Global Immunization Division, Atlanta, GA, USA;
Centers for Disease Control and Prevention, Center for Global Health, Global Immunization Division, Atlanta, GA, USA;
Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL, USA,University of Central Florida, College of Medicine, Orlando, FL, USA;
dynamic modeling; outbreak risks; poliovirus;
机译:末期管理循环疫苗衍生脊髓灰质炎的风险:口服脊髓灰质炎疫苗的需求
机译:口服脊髓灰质炎病毒疫苗对强毒疫苗衍生的脊髓灰质炎病毒的两次剂量评估
机译:表征脊髓灰质炎病毒的传播和进化:来自与野生和疫苗相关的脊髓灰质炎病毒建模经验的见解
机译:循环2型疫苗衍生脊髓灰质炎病毒(VDPV)在遗传上是否与免疫缺陷相关VDPV有所区别?
机译:用于建模医疗保健风险的数据驱动方法:药物监测和乳腺癌发病率预测中的见解和应用
机译:末期管理循环疫苗衍生脊髓灰质炎的风险:口服脊髓灰质炎疫苗的需求
机译:末期管理循环疫苗衍生脊髓灰质炎的风险:口服脊髓灰质炎疫苗的需求
机译:婴儿口服脊髓灰质炎病毒1型疫苗的人体感染剂量测定